Condition: Liver Cirrhosis · Sponsor: Centre Hospitalier Universitaire de Nice
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.
This description comes directly from the study's public registry record.
Guillaume FAVRE, PhD · +33492039220 · favre.g@chu-nice.fr
Gullaume Marrane · +33492039220 · marrane.g@chu-nice.fr
Always discuss trial participation with your own doctor first.
| CHU de Nice | Nice, Alpes-maritimes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07201649